Geron Quits the Embryonic Stem Cell Industry
By Pete Shanks
| 11. 16. 2011
Geron has quit on embryonic stem cells. The company is abandoning
its world-leading clinical trial, aimed at using stem cells to treat
people paralyzed with spinal-cord injuries. It is laying off more than a third of its staff, and is writing off about $8 million. It has also repaid
the California Institute of Regenerative Medicine (CIRM) a loan of more
than $6 million, plus interest. Geron will continue to monitor the four
patients currently enrolled in the phase 1 clinical trial, and says it
is looking for another company to take it over.
The decision to terminate the trial seems to be all business, a
departure from past practices that seemed motivated more by hype and
wishful thinking. Geron's stock has been plummeting (down from $6.34 to $1.60
over the year), and new management is conducting triage. The ESC trial
is only in phase 1, a safety trial, in which severely injured patients
receive low doses of treatments that are frankly unlikely to do much
good; the point is to ensure that they do no harm. Results from that...
Related Articles
By Cade Metz and Karen Weise, The New York Times | 05.05.2025
Last month, an A.I. bot that handles tech support for Cursor, an up-and-coming tool for computer programmers, alerted several customers about a change in company policy. It said they were no longer allowed to use Cursor on more than...
By Laura Ungar, Associated Press | 04.26.2025
Emily Kramer-Golinkoff can’t get enough oxygen with each breath. Advanced cystic fibrosis makes even simple things like walking or showering arduous and exhausting.
She has the most common fatal genetic disease in the U.S., which afflicts 40,000 Americans. But her...
By Mary Annette Pember, ICT News [cites CGS' Katie Hasson] | 04.18.2025
The sight of a room full of human cadavers can be off-putting for some, but not for Haley Omeasoo.
In fact, Omeasoo’s comfort level and lack of squeamishness convinced her to pursue studies in forensics and how DNA can be...
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...
